:max_bytes(150000):strip_icc()/CopyofObesityTentpoleDataIllustrations1-final-0a25a60e57144336ad6ff70f588e947b.png)
glp 1 not overweight GLP-1 Drugs Won't Fix the Flaws in Obesity Care GLP-1 Therapy Part 1: Setting
Description
Although preliminary data are encouraging, especially regarding the reduction of inflammation and body weight, open questions remain regarding the effects of these drugs on a longer time scale and on different patient subgroups
doi:10.2337/db09-0058
After one month, the dose may be increased to 10mcg injected twice daily
The FDA has received adverse event reports of gastroparesis/stomach paralysis from individuals who took these drugs
Midi Health typically does not accept insurance for platform fees, though some patients can use HSAs or FSAs
